These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

393 related articles for article (PubMed ID: 30728081)

  • 1. Prognostic value of CD8 + PD-1+ immune infiltrates and PDCD1 gene expression in triple negative breast cancer.
    Yeong J; Lim JCT; Lee B; Li H; Ong CCH; Thike AA; Yeap WH; Yang Y; Lim AYH; Tay TKY; Liu J; Wong SC; Chen J; Lim EH; Iqbal J; Dent R; Newell EW; Tan PH
    J Immunother Cancer; 2019 Feb; 7(1):34. PubMed ID: 30728081
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ALG3 predicts poor prognosis and increases resistance to anti-PD-1 therapy through modulating PD-L1 N-link glycosylation in TNBC.
    Luo B; Liu X; Zhang Q; Liang G; Zhuang Y
    Int Immunopharmacol; 2024 Oct; 140():112875. PubMed ID: 39116492
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High Densities of Tumor-Associated Plasma Cells Predict Improved Prognosis in Triple Negative Breast Cancer.
    Yeong J; Lim JCT; Lee B; Li H; Chia N; Ong CCH; Lye WK; Putti TC; Dent R; Lim E; Thike AA; Tan PH; Iqbal J
    Front Immunol; 2018; 9():1209. PubMed ID: 29899747
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The therapeutic candidate for immune checkpoint inhibitors elucidated by the status of tumor-infiltrating lymphocytes (TILs) and programmed death ligand 1 (PD-L1) expression in triple negative breast cancer (TNBC).
    Tomioka N; Azuma M; Ikarashi M; Yamamoto M; Sato M; Watanabe KI; Yamashiro K; Takahashi M
    Breast Cancer; 2018 Jan; 25(1):34-42. PubMed ID: 28488168
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular and Immune Correlates of PDCD1 (PD-1), PD-L1 (CD274), and PD-L2 (PDCD1LG2) DNA Methylation in Triple Negative Breast Cancer.
    Ralser DJ; Klümper N; Gevensleben H; Zarbl R; Kaiser C; Landsberg J; Hölzel M; Strieth S; Faridi A; Abramian A; Dietrich D
    J Immunother; 2021 Oct; 44(8):319-324. PubMed ID: 34347720
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Syntenin1/MDA-9 (SDCBP) induces immune evasion in triple-negative breast cancer by upregulating PD-L1.
    Liu J; Yang Y; Wang H; Wang B; Zhao K; Jiang W; Bai W; Liu J; Yin J
    Breast Cancer Res Treat; 2018 Sep; 171(2):345-357. PubMed ID: 29845474
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic Significance of PD-1, PD-L1 and CD8 Gene Expression Levels in Gastric Cancer.
    Ito S; Masuda T; Noda M; Hu Q; Shimizu D; Kuroda Y; Eguchi H; Tobo T; Utsunomiya T; Mimori K
    Oncology; 2020; 98(7):501-511. PubMed ID: 32380498
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic impact of programed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor infiltrating lymphocytes in colorectal cancer.
    Li Y; Liang L; Dai W; Cai G; Xu Y; Li X; Li Q; Cai S
    Mol Cancer; 2016 Aug; 15(1):55. PubMed ID: 27552968
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The combined presence of CD20 + B cells and PD-L1 + tumor-infiltrating lymphocytes in inflammatory breast cancer is prognostic of improved patient outcome.
    Arias-Pulido H; Cimino-Mathews A; Chaher N; Qualls C; Joste N; Colpaert C; Marotti JD; Foisey M; Prossnitz ER; Emens LA; Fiering S
    Breast Cancer Res Treat; 2018 Sep; 171(2):273-282. PubMed ID: 29858752
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Significance of evaluating tumor-infiltrating lymphocytes (TILs) and programmed cell death-ligand 1 (PD-L1) expression in breast cancer.
    Kurozumi S; Fujii T; Matsumoto H; Inoue K; Kurosumi M; Horiguchi J; Kuwano H
    Med Mol Morphol; 2017 Dec; 50(4):185-194. PubMed ID: 28936553
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinicopathological and Prognostic Significance of Programmed Death Ligand-1 SP142 Expression in 132 Patients With Triple-negative Breast Cancer.
    Chu J; Yeo MK; Lee SH; Lee MY; Chae SW; Kim HS; DO SI
    In Vivo; 2022; 36(6):2890-2898. PubMed ID: 36309362
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Expression comparison and clinical significance of PD-L1 (22C3) and PD-L1 (SP142) in triple negative breast cancer].
    Zhang J; Yuan P; Lei HZ; Liu XY; Li X; Ying JM; Sun GY; Wang SL; Lyu N
    Zhonghua Zhong Liu Za Zhi; 2022 Mar; 44(3):260-267. PubMed ID: 35316876
    [No Abstract]   [Full Text] [Related]  

  • 13. Checkpoint inhibitors in triple-negative breast cancer (TNBC): Where to go from here.
    Kwa MJ; Adams S
    Cancer; 2018 May; 124(10):2086-2103. PubMed ID: 29424936
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumoral PD-1hiCD8+ T cells are partially exhausted and predict favorable outcome in triple-negative breast cancer.
    Guo L; Cao C; Goswami S; Huang X; Ma L; Guo Y; Yang B; Li T; Chi Y; Zhang X; Wu J
    Clin Sci (Lond); 2020 Apr; 134(7):711-726. PubMed ID: 32202617
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinicopathological and Prognostic Significance of Programmed Death Ligand 1 Expression in Korean Patients With Triple-negative Breast Carcinoma.
    Kim HS; DO SI; Kim DH; Apple S
    Anticancer Res; 2020 Mar; 40(3):1487-1494. PubMed ID: 32132048
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune checkpoints in aggressive breast cancer subtypes.
    Zawlik I; Gablo N; Szymanska B; Pawlowska Z; Chudobinski C; Chalubinska-Fendler J; Morawiec Z; Zielinska-Blizniewska H; Morawiec-Sztandera A; Kolacinska A
    Neoplasma; 2016; 63(5):768-73. PubMed ID: 27468881
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of programmed death ligand-1 and programmed death-1 in samples of invasive ductal carcinoma of the breast and its correlation with prognosis.
    Zhou T; Xu D; Tang B; Ren Y; Han Y; Liang G; Wang J; Wang L
    Anticancer Drugs; 2018 Oct; 29(9):904-910. PubMed ID: 30085937
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Programmed Death Ligand 1 (PD-L1) Tumor Expression Is Associated with a Better Prognosis and Diabetic Disease in Triple Negative Breast Cancer Patients.
    Botti G; Collina F; Scognamiglio G; Rao F; Peluso V; De Cecio R; Piezzo M; Landi G; De Laurentiis M; Cantile M; Di Bonito M
    Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28230773
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Programmed death-ligand 1 (PD-L1) expression predicts response to neoadjuvant chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis.
    Azim HA; Shohdy KS; Elghazawy H; Salib MM; Almeldin D; Kassem L
    Biomarkers; 2022 Dec; 27(8):764-772. PubMed ID: 35980714
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The prognostic value of a combined immune score in tumor and immune cells assessed by immunohistochemistry in triple-negative breast cancer.
    Choi JE; Lee JS; Jin MS; Nikas IP; Kim K; Yang S; Park SY; Koh J; Yang S; Im SA; Ryu HS
    Breast Cancer Res; 2023 Nov; 25(1):134. PubMed ID: 37924153
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.